Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says

Zealand Pharma A/S

11/06/2025 07:39

** Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23

** Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg

** Adds, Eli Lilly's LLY.N orforglipron also in spotlight

** Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say

** YTD, NOVOb is down 16.7%

** Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch

** Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure

** Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar

** It will also watch updates from BrightGene 688166.SS on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma TERN.O on oral GLP-1, TERN-601

 (Reporting by Anna Pruchnicka)

 ((anna.pruchnicka@tr.com))